W.G. Shaheen & Associates DBA Whitney & Co Invests $911,000 in Abbott Laboratories $ABT

W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in Abbott Laboratories (NYSE:ABT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,270 shares of the healthcare product maker’s stock, valued at approximately $911,000.

A number of other institutional investors have also recently made changes to their positions in the company. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories during the fourth quarter worth approximately $27,000. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories in the third quarter valued at $29,000. Guerra Advisors Inc purchased a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $31,000. Bridge Generations Wealth Management LLC purchased a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $33,000. Finally, Copia Wealth Management purchased a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $38,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ABT shares. Raymond James Financial cut their price objective on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Oppenheimer cut their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Weiss Ratings cut Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, April 24th. UBS Group lowered their target price on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Finally, JPMorgan Chase & Co. lowered their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $119.43.

Abbott Laboratories Trading Down 2.5%

NYSE:ABT opened at $91.52 on Thursday. The stock has a 50-day simple moving average of $104.76 and a 200-day simple moving average of $116.38. The stock has a market cap of $159.40 billion, a P/E ratio of 25.64, a P/E/G ratio of 1.55 and a beta of 0.79. Abbott Laboratories has a 1 year low of $90.72 and a 1 year high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the business earned $1.09 EPS. The business’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other news, SVP Eric Shroff sold 709 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders bought 22,200 shares of company stock worth $2,215,100 and sold 3,055 shares worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.